



Caladrius Biosciences to Participate at Upcoming April Conferences

April 5, 2017



BASKING RIDGE, N.J., Apr. 5, 2017 — Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company with a select therapeutic development pipeline focused on immune modulation announces today that the Company’s leadership and experts will participate at the following upcoming April conferences:

10th Diabetes Drug Discovery & Development

- **Date and Time:** Thursday, April 6, 2017, 9:20 AM ET
- **Venue:** Hyatt Regency, Boston, Massachusetts
- **Plenary:** Tolerogenic Therapy for Type 1 Diabetes, A Phase 2 Randomized Study of Autologous Regulatory T-cells Adolescents with Recent Onset T1DM
- **Speaker:** Douglas W. Losordo, MD, Chief Medical Officer, Caladrius

6th Annual Stem Cell Product Development & Commercialization

- **Date and Time:** Thursday, April 6, 1:50 PM ET
- **Venue:** Hyatt Regency, Boston, Massachusetts
- **Presentation:** Global Regulation of Cell Therapies
- **Presenter:** William Sietsema, PhD, Executive Director, Global Regulatory Affairs, Caladrius

24th Annual Future Leaders in the Biotech Industry

- **Date:** Friday, April 7
- **Venue:** Millennium Broadway Hotel & Conference Center, New York, New York
- **Format:** One-on-One Meetings
- **Participant:** Joseph Talamo, Chief Financial Officer, Caladrius

Alliance for Regenerative Medicine’s 5th Annual Cell & Gene Investor Day

- **Date and Time:** Thursday, April 27, 2017, 4:45 PM ET
- **Website:** <http://arminvestorday.com>
- **Venue:** The State Room, Boston, Massachusetts
- **Presentation:** Company Presentation
- **Presenter:** David J. Mazzo, PhD, President and Chief Executive Officer, Caladrius

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a cell therapy development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company is investigating its lead product candidate, CLBS03, for the treatment of recent-onset type 1 diabetes in a currently enrolling Phase 2 trial. The Company’s subsidiary, PCT, is a well-known development and manufacturing

partner exclusively focused on the cell therapy industry and has served over 100 clients since 1999. For more information on Caladrius please visit www.caladrius.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 17, 2017, and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control.



Source: Caladrius Biosciences, Inc.